Related references
Note: Only part of the references are listed.C-RAF Mutations Confer Resistance to RAF Inhibitors
Rajee Antony et al.
CANCER RESEARCH (2013)
Effects of Raf Dimerization and Its Inhibition on Normal and Disease-Associated Raf Signaling
Alyson K. Freeman et al.
MOLECULAR CELL (2013)
BRAF splice variants in rheumatoid arthritis synovial fibroblasts activate MAPK through CRAF
Richard H. Weisbart et al.
MOLECULAR IMMUNOLOGY (2013)
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance
Meghna Das Thakur et al.
NATURE (2013)
Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas
Angela J. Sievert et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma
Maria R. Girotti et al.
CANCER DISCOVERY (2013)
Elucidating Distinct Roles for NF1 in Melanomagenesis
Ophelia Maertens et al.
CANCER DISCOVERY (2013)
A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition
Steven R. Whittaker et al.
CANCER DISCOVERY (2013)
Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
Erick J. Morris et al.
CANCER DISCOVERY (2013)
Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF-Mutant Thyroid Carcinomas
Cristina Montero-Conde et al.
CANCER DISCOVERY (2013)
Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas
Piro Lito et al.
CANCER CELL (2012)
Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer
Hong Yang et al.
CANCER RESEARCH (2012)
A shared molecular mechanism underlies the human rasopathies Legius syndrome and Neurofibromatosis-1
Irma B. Stowe et al.
GENES & DEVELOPMENT (2012)
The intermediate-activity L597VBRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway
Catherine Andreadi et al.
GENES & DEVELOPMENT (2012)
Induction of Cutaneous Squamous Cell Carcinomas by RAF Inhibitors: Cause for Concern?
Mario E. Lacouture et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors
Patrick A. Oberholzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
Axel Hauschild et al.
LANCET (2012)
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
Gerald S. Falchook et al.
LANCET ONCOLOGY (2012)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Ravid Straussman et al.
NATURE (2012)
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Timothy R. Wilson et al.
NATURE (2012)
Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment
Margaret K. Callahan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
Fei Su et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF
F. Xing et al.
ONCOGENE (2012)
ERK1/2 MAP kinases: Structure, function, and regulation
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2012)
Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance
Hubing Shi et al.
NATURE COMMUNICATIONS (2012)
EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
Ryan B. Corcoran et al.
CANCER DISCOVERY (2012)
Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
Hubing Shi et al.
CANCER DISCOVERY (2012)
AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
Sarat Chandarlapaty et al.
CANCER CELL (2011)
Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
Brett S. Carver et al.
CANCER CELL (2011)
Mechanistic principles of RAF kinase signaling
Christian M. Udell et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2011)
Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
Nikhil Wagle et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK
Damian F. Brennan et al.
NATURE (2011)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikos I. Poulikakos et al.
NATURE (2011)
Feedback regulation of EGFR signalling: decision making by early and delayed loops
Roi Avraham et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2011)
BRAF Mutations in Hairy-Cell Leukemia
Enrico Tiacci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Resistance to BRAF Inhibition in Melanomas
David B. Solit et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
Jessie Villanueva et al.
CANCER CELL (2010)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn et al.
CELL (2010)
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
Scott Kopetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Gideon Bollag et al.
NATURE (2010)
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Cory M. Johannessen et al.
NATURE (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
Eric W. Joseph et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Gatekeeper Mutations Mediate Resistance to BRAF-Targeted Therapies
Steven Whittaker et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
A dimerization-dependent mechanism drives RAF catalytic activation
Thanashan Rajakulendran et al.
NATURE (2009)
Cell fate decisions are specified by the dynamic ERK interactome
Alex von Kriegsheim et al.
NATURE CELL BIOLOGY (2009)
V600EBRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway
Christine A. Pratilas et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma
Clara Montagut et al.
CANCER RESEARCH (2008)
ERK-dependent threonine phosphorylation of EGF receptor modulates receptor downregulation and signaling
Xin Li et al.
CELLULAR SIGNALLING (2008)
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
Keiran S. M. Smalley et al.
MOLECULAR CANCER THERAPEUTICS (2008)
KSR and CNK:: two scaffolds regulating RAS-mediated RAF activation
A. Claperon et al.
ONCOGENE (2007)
A module of negative feedback regulators defines growth factor signaling
Ido Amit et al.
NATURE GENETICS (2007)
Regulation and role of Raf-1/B-Raf heterodimerization
LK Rushworth et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Identification of novel in vivo Raf-1 phosphorylation sites mediating positive feedback Raf-1 regulation by extracellular signal-regulated kinase
V Balan et al.
MOLECULAR BIOLOGY OF THE CELL (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
BRAF mutation predicts sensitivity to MEK inhibition
DB Solit et al.
NATURE (2006)
V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors
OM Grbovic et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
B-Raf and Raf-1 are regulated by distinct autoregulatory mechanisms
NH Tran et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Regulation of raf-1 by direct feedback phosphorylation
MK Dougherty et al.
MOLECULAR CELL (2005)
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF
PTC Wan et al.
CELL (2004)
SPRY2 is an inhibitor of the Ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant
D Tsavachidou et al.
CANCER RESEARCH (2004)
The RAF proteins take centre stage
C Wellbrock et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
Modulation of signalling by sprouty: A developing story
HJ Kim et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
Tyrosine phosphorylation of sprouty proteins regulates their ability to inhibit growth factor signaling: A dual feedback loop
JM Mason et al.
MOLECULAR BIOLOGY OF THE CELL (2004)
Regulation of Raf through phosphorylation and N terminus-C terminus interaction
HR Chong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Protein phosphatase 2A positively regulates ras signaling by dephosphorylating KSR1 and Raf-1 on critical 14-3-3 binding sites
S Ory et al.
CURRENT BIOLOGY (2003)
Mammalian Sprouty4 Suppresses Ras-Independent ERK Activation by Binding to Raf1
Atsuo Sasaki et al.
CELL CYCLE (2003)
Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway
H Hanafusa et al.
NATURE CELL BIOLOGY (2002)
Structural determinants of Ras-Raf interaction analyzed in live cells
T Bondeva et al.
MOLECULAR BIOLOGY OF THE CELL (2002)
14-3-3 antagonizes ras-mediated Raf-1 recruitment to the plasma membrane to maintain signaling fidelity
Y Light et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Cyclic AMP-dependent kinase regulates Raf-1 kinase mainly by phosphorylation of serine 259
AS Dhillon et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
14-3-3 proteins: Active cofactors in cellular regulation by serine/threonine phosphorylation
G Tzivion et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
NF1 tumor suppressor gene function: Narrowing the GAP
K Cichowski et al.
CELL (2001)
Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601
BH Zhang et al.
EMBO JOURNAL (2000)
Cell signaling by receptor tyrosine kinases
J Schlessinger
CELL (2000)
Raf-1-associated protein phosphatase 2A as a positive regulator of kinase activation
D Abraham et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Elucidation of binding determinants and functional consequences of Ras/Raf-cysteine-rich domain interactions
JG Williams et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
